Mereo BioPharma Group plc

NasdaqCM:MREO Stock Report

Market Cap: US$582.4m

Mereo BioPharma Group Management

Management criteria checks 4/4

Mereo BioPharma Group's CEO is Denise Scots-Knight, appointed in Jul 2015, has a tenure of 9.5 years. total yearly compensation is $2.22M, comprised of 25.5% salary and 74.5% bonuses, including company stock and options. directly owns 1.9% of the company’s shares, worth $11.06M. The average tenure of the management team and the board of directors is 6.8 years and 3.8 years respectively.

Key information

Denise Scots-Knight

Chief executive officer

US$2.2m

Total compensation

CEO salary percentage25.5%
CEO tenure9.5yrs
CEO ownership1.9%
Management average tenure6.8yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

Is Mereo BioPharma Group (NASDAQ:MREO) Weighed On By Its Debt Load?

Apr 07
Is Mereo BioPharma Group (NASDAQ:MREO) Weighed On By Its Debt Load?

Is Mereo BioPharma Group (NASDAQ:MREO) Using Debt Sensibly?

Nov 25
Is Mereo BioPharma Group (NASDAQ:MREO) Using Debt Sensibly?

Mereo stock rises 12% on FDA fast-track status for lung disease drug alvelestat

Oct 17

Rubric Capital boosts Mereo BioPharma board nominees slate to five

Oct 03

Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside

Sep 22

Mereo activist investor Rubric asks board again to hold general meeting, nominate directors

Sep 14

Mereo BioPharma Group regains compliance with Nasdaq's listing rule

Jul 05

Mereo BioPharma: Activist Pressure In A Net-Net Biopharma

Jun 17

Mereo BioPharma: Anti-TIGIT Developer In Mid-Stage Development

Dec 08

Mereo BioPharma and Cancer Focus Fund ink partnership for ovarian cancer study

Apr 30

CEO Compensation Analysis

How has Denise Scots-Knight's remuneration changed compared to Mereo BioPharma Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$45m

Jun 30 2024n/an/a

-US$37m

Mar 31 2024n/an/a

-US$26m

Dec 31 2023US$2mUS$565k

-US$29m

Sep 30 2023n/an/a

-US$31m

Jun 30 2023n/an/a

-US$32m

Mar 31 2023n/an/a

-US$42m

Dec 31 2022US$2mUS$507k

-US$42m

Sep 30 2022n/an/a

-US$31m

Jun 30 2022n/an/a

-US$23m

Mar 31 2022n/an/a

-US$4m

Dec 31 2021US$2mUS$539k

US$17m

Sep 30 2021n/an/a

-US$10m

Jun 30 2021n/an/a

-US$37m

Mar 31 2021n/an/a

-US$131m

Dec 31 2020US$1mUS$545k

-US$224m

Sep 30 2020n/an/a

-US$198m

Jun 30 2020n/an/a

-US$177m

Mar 31 2020n/an/a

-US$111m

Dec 31 2019US$2mUS$518k

-US$46m

Sep 30 2019n/an/a

-US$41m

Jun 30 2019n/an/a

-US$40m

Mar 31 2019n/an/a

-US$41m

Dec 31 2018US$957kUS$484k

-US$41m

Compensation vs Market: Denise's total compensation ($USD2.22M) is about average for companies of similar size in the US market ($USD2.26M).

Compensation vs Earnings: Denise's compensation has been consistent with company performance over the past year.

CEO

Denise Scots-Knight (65 yo)

9.5yrs

Tenure

US$2,219,323

Compensation

Dr. Denise Vera Scots-Knight, Ph.D. serves as President of OncoMed Pharmaceuticals, Inc. She serves as Director at Elanco Animal Health Incorporated since March 13, 2019. She co-founded Mereo BioPharma Gro...

Leadership Team

NamePositionTenureCompensationOwnership
Denise Scots-Knight
Co-Founder9.5yrsUS$2.22m1.9%
$ 11.1m
Charles Sermon
Co-Founder9.7yrsUS$1.09m0.58%
$ 3.4m
Christine Fox
Chief Financial Officer4yrsUS$1.00m0.27%
$ 1.6m
John Richard
Co-Founder & Chief Business Officer10yrsno datano data
John Lewicki
Chief Scientific Officer4.5yrsno data0.060%
$ 349.0k
Jackie Parkin
Senior VP & Therapeutic Headno datano datano data
Alexandra Hughes-Wilson
Chief of Patient Access & Commercial Planning6.8yrsno data0.033%
$ 189.8k
Suba Krishnan
Senior Vice President of Clinical Development4.1yrsno datano data
Bo Kara
Senior VP and Head of Pharmaceutical Development & CMCno datano datano data

6.8yrs

Average Tenure

62yo

Average Age

Experienced Management: MREO's management team is seasoned and experienced (6.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Denise Scots-Knight
Co-Founder9.8yrsUS$2.22m1.9%
$ 11.1m
Michael Wyzga
Independent Non-Executive Chairman of The Board5.8yrsUS$156.80k0.016%
$ 94.2k
Deepika Pakianathan
Independent Non-Executive Director5.8yrsUS$113.76k0%
$ 0
Anders Ekblom
Independent Non-Executive Director9.5yrsUS$121.31k0.17%
$ 962.3k
Marc Yoskowitz
Independent Director2.2yrsUS$94.49k0.049%
$ 283.6k
Annalisa Lisa Jenkins
Independent Director2.2yrsUS$100.96k0.049%
$ 283.6k
Jeremy Bender
Independent Non Executive Director4.3yrsUS$105.08k0.0081%
$ 47.2k
Daniel Shames
Independent Director2.2yrsUS$97.75k0.049%
$ 283.6k
Pierre Jacquet
Independent Director3.3yrsUS$102.18k0.10%
$ 581.5k
Justin Roberts
Independent Director2.2yrsno datano data

3.8yrs

Average Tenure

59yo

Average Age

Experienced Board: MREO's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 00:32
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mereo BioPharma Group plc is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Yun ZhongBTIG
Julian HarrisonBTIG